AllianceBernstein
RPRX icon

AllianceBernstein’s Royalty Pharma RPRX Stock Holding History

AllianceBernstein’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.9M Sell
1,062,062
-135,656
-11% -$7.06M 0.02% 622
2026
Q1 		$46.3M Buy
1,197,718
+176,950
+17% +$7.75M 0.02% 621
2025
Q4 		$39.4M Buy
1,020,768
+83,910
+9% +$3.2M 0.01% 699
2025
Q3 		$33.1M Buy
936,858
+37,016
+4% +$1.34M 0.01% 744
2025
Q2 		$32.4M Sell
899,842
-341,209
-27% -$11.3M 0.01% 737
2025
Q1 		$38.6M Buy
1,241,051
+86,873
+8% +$2.75M 0.01% 653
2024
Q4 		$29.4M Sell
1,154,178
-125,842
-10% -$3.34M 0.01% 785
2024
Q3 		$36.2M Sell
1,280,020
-30,856
-2% -$855K 0.01% 706
2024
Q2 		$34.6M Sell
1,310,876
-133,640
-9% -$3.7M 0.01% 712
2024
Q1 		$43.9M Buy
1,444,516
+75,117
+5% +$2.21M 0.02% 646
2023
Q4 		$38.5M Buy
1,369,399
+1,150,580
+526% +$31.6M 0.01% 665
2023
Q3 		$5.94M Sell
218,819
-3,384
-2% -$101K ﹤0.01% 1345
2023
Q2 		$6.83M Sell
222,203
-69,303
-24% -$2.35M ﹤0.01% 1307
2023
Q1 		$10.5M Buy
291,506
+131,429
+82% +$4.87M ﹤0.01% 1077
2022
Q4 		$6.33M Sell
160,077
-166,182
-51% -$6.94M ﹤0.01% 1315
2022
Q3 		$13.1M Sell
326,259
-60,800
-16% -$2.6M 0.01% 972
2022
Q2 		$16.3M Buy
387,059
+64,360
+20% +$2.64M 0.01% 933
2022
Q1 		$12.6M Buy
322,699
+166,129
+106% +$6.52M ﹤0.01% 1106
2021
Q4 		$6.24M Sell
156,570
-3,309
-2% -$129K ﹤0.01% 1502
2021
Q3 		$5.78M Buy
159,879
+1,070
+0.7% +$41.6K ﹤0.01% 1531
2021
Q2 		$6.51M Buy
158,809
+65,722
+71% +$2.8M ﹤0.01% 1461
2021
Q1 		$4.06M Buy
93,087
+42,915
+86% +$2.03M ﹤0.01% 1690
2020
Q4 		$2.51M Buy
50,172
+9,460
+23% +$401K ﹤0.01% 1851
2020
Q3 		$1.71M Buy
+40,712
New +$1.75M ﹤0.01% 1937

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein's RPRX Position: Q2 2026 in Review

AllianceBernstein reduced its Royalty Pharma (RPRX) stake by 11% in Q2 2026, selling an estimated $7.06M and leaving 1,062,062 shares worth $50.9M. The position accounts for 0.02% of the portfolio, ranked #622.

AllianceBernstein first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • AllianceBernstein held 1,062,062 shares of Royalty Pharma worth $50.9M as of Q2 2026.
  • AllianceBernstein sold 135,656 Royalty Pharma shares in Q2 2026, an estimated $7.06M.
  • Royalty Pharma made up 0.02% of AllianceBernstein's portfolio in Q2 2026, its #622 holding.
  • AllianceBernstein first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.